Hennion & Walsh Asset Management Inc. Has $8.49 Million Holdings in Mirum Pharmaceuticals, Inc. $MIRM

Hennion & Walsh Asset Management Inc. trimmed its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 5.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 115,854 shares of the company’s stock after selling 6,915 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Mirum Pharmaceuticals were worth $8,493,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in MIRM. Jump Financial LLC increased its stake in Mirum Pharmaceuticals by 839.7% during the 2nd quarter. Jump Financial LLC now owns 148,689 shares of the company’s stock worth $7,567,000 after acquiring an additional 132,866 shares during the period. Contravisory Investment Management Inc. acquired a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter worth $270,000. Woodline Partners LP grew its holdings in shares of Mirum Pharmaceuticals by 40.0% during the 1st quarter. Woodline Partners LP now owns 566,271 shares of the company’s stock worth $25,511,000 after purchasing an additional 161,867 shares in the last quarter. Eventide Asset Management LLC increased its position in shares of Mirum Pharmaceuticals by 4.4% in the second quarter. Eventide Asset Management LLC now owns 2,637,485 shares of the company’s stock worth $134,224,000 after purchasing an additional 110,485 shares during the period. Finally, Emerald Mutual Fund Advisers Trust acquired a new position in Mirum Pharmaceuticals in the second quarter valued at about $11,071,000.

Mirum Pharmaceuticals Stock Performance

NASDAQ MIRM opened at $75.56 on Tuesday. The firm’s fifty day moving average price is $72.11 and its two-hundred day moving average price is $67.09. The stock has a market cap of $3.88 billion, a PE ratio of -87.86 and a beta of 0.48. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $36.88 and a fifty-two week high of $82.58.

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.15. The company had revenue of $133.01 million during the quarter, compared to analysts’ expectations of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.Mirum Pharmaceuticals’s revenue was up 47.1% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.30) EPS. On average, equities analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on MIRM. Leerink Partners set a $100.00 price objective on shares of Mirum Pharmaceuticals in a research note on Wednesday, December 10th. Morgan Stanley increased their price target on shares of Mirum Pharmaceuticals from $81.00 to $95.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 9th. Citigroup reaffirmed an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Friday, December 19th. Evercore ISI lifted their price target on Mirum Pharmaceuticals from $89.00 to $94.00 and gave the company an “outperform” rating in a research note on Monday, December 8th. Finally, Wall Street Zen downgraded Mirum Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Mirum Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $100.25.

Read Our Latest Research Report on MIRM

About Mirum Pharmaceuticals

(Free Report)

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.

Featured Stories

• Five stocks we like better than Mirum Pharmaceuticals
• A month before the crash
• BNZI: BNZI Surges Ahead as AI Marketing Fuels Record Revenue
• You Still Think Silver’s a Joke? Watch What Happens Next.
• A U.S. “birthright” claim worth trillions – activated quietly
• A Message From An Ex-CIA Officer About Trump

Want to see what other hedge funds are holding MIRM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report).